COHANCE — Cohance Lifesciences Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeLarge CapNeutral

Annual income statement for Cohance Lifesciences, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	10,097	13,202	13,403	10,514	11,976
Cost of Revenue
Gross Profit	5,944	7,699	7,720	6,187	8,923
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	6,009	7,797	8,215	7,000	8,999
Operating Profit	4,088	5,405	5,188	3,514	2,977
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	4,677	6,676	5,597	4,057	3,439
Provision for Income Taxes
Net Income After Taxes	3,623	4,538	4,113	3,003	2,648
Net Income Before Extraordinary Items
Net Income	3,623	4,538	4,113	3,003	2,648
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	3,623	4,538	4,113	3,003	2,648
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	14.2	17.8	16.2	11.9	10.4
Dividends per Share
Special Dividends per Share